Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Jason Ahee, M.D.

Summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Eligibility

Age range: 40+ years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * visually significant cataracts Exclusion Criteria: * allergy to fluoroquinolones, cobalamin (B12)

Interventions

Drug
Moxifloxacin
Intracameral injection
Drug
Placebo
intracameral injection

Location

Zion Eye Institute
St. George, Utah